Clinical Trial News and Research

RSS

Clonidine increases hypotension and non-fatal cardiac arrest after noncardiac surgery

Clonidine - a drug that reduces blood pressure and heart rate - increased rates of clinically concerning hypotension and non-fatal cardiac arrest after noncardiac surgery, according to the POISE-2 trial presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Perioperative aspirin increases risk of serious bleeding after non-heart-related surgery

Patients given aspirin to prevent heart problems after non-heart-related surgery had a higher risk of serious bleeding than the patients who did not receive aspirin.

1 Apr 2014

Scientists develop new procedure using ultrasound energy to "ablate" prostate cancer

Men with prostate cancer face tough choices: when, or even if, to treat their cancer; what procedure to use; and how to balance their chosen treatment with their quality of life. Now, a new multicenter clinical trial seeks to offer men another option - one that physicians hope will treat prostate cancers with fewer side effects.

1 Apr 2014

New device simulates gastro-intestinal tract

A breakthrough in drug testing developed by a University of Huddersfield lecturer could lead to cheaper, more effective medicines. Dr Hamid Merchant is a member of the team that has created a device which accurately simulates the gastro-intestinal tract and how it absorbs medication.

1 Apr 2014

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

Patients with severe ischemic heart disease and heart failure can benefit from a new treatment in which stem cells found in bone marrow are injected directly into the heart muscle, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

rEVO Biologics Inc., a subsidiary of LFB SA, today announced the initiation of the Phase 3 clinical program for ATryn for the treatment of preeclampsia in pregnant women during the 24th to 28th week of pregnancy.

31 Mar 2014

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

Heron Therapeutics, Inc., a specialty pharmaceutical company, today announced the initiation of a Phase 3 clinical trial of SUSTOL™ (APF530), the Company's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately and highly emetogenic chemotherapy.

31 Mar 2014

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced that aldoxorubicin has received orphan medicinal product designation from the European Commission for the treatment of advanced soft tissue sarcomas. The designation is to encourage the development of drugs which may provide significant benefit to patients suffering from rare diseases.

31 Mar 2014

Bariatric surgery patients report better quality of life

A study by Cleveland Clinic researchers shows bariatric surgery is a highly effective and durable treatment for type 2 diabetes in obese patients, enabling nearly all surgical patients to be free of insulin and many to be free of all diabetic medications three years after surgery.

31 Mar 2014

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results.

31 Mar 2014

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Concert Pharmaceuticals, Inc. today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

31 Mar 2014

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

Daiichi Sankyo Company, Limited today announced that it has started enrolling patients into the ENSURE-AF multinational phase 3 study, which will evaluate the efficacy and safety of its investigational oral, once-daily direct factor Xa-inhibitor edoxaban compared to enoxaparin/warfarin for the prevention of stroke and other blood clot complications in patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion (low-energy shocks to trigger normal heart rhythm).

31 Mar 2014

ICON agrees to acquire Aptiv Solutions for $143.5 million

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain closing conditions, to acquire Aptiv Solutions for a cash consideration of $143.5 million. Aptiv Solutions is owned by The Halifax Group, SV Life Sciences, Comvest Partners and Management.

31 Mar 2014

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

Amgen (NASDAQ: AMGN) today announced new detailed data from three Phase 3 studies that showed treatment with its novel investigational cholesterol-lowering medication, evolocumab (AMG 145), resulted in a statistically significant reduction of 55-66 percent in low-density lipoprotein cholesterol (LDL-C) compared to placebo in patients with high cholesterol.

31 Mar 2014

New FDA Roadmap App helps sponsors improve clinical research

The new FDA Roadmap App from PHT Corporation helps sponsors navigate the Roadmap to Patient-Focused Outcome Measurement in Clinical Trials released by the FDA with their Clinical Outcome Assessment Qualification Program.

31 Mar 2014

Cheap drug holds promise of treating heart attack patients

The initial results of this trial were published a few months ago (Circulation. 2013;128:1495-1503), and showed that patients who received this treatment during emergency transit to hospital had much smaller amounts of dead heart muscle than those randomly assigned to receive no treatment.

31 Mar 2014

Clinical Trial News and Research

Clonidine increases hypotension and non-fatal cardiac arrest after noncardiac surgery

Perioperative aspirin increases risk of serious bleeding after non-heart-related surgery

Scientists develop new procedure using ultrasound energy to "ablate" prostate cancer

New device simulates gastro-intestinal tract

Injecting bone marrow derived stem cells directly into heart muscle improves heart function

rEVO Biologics commences ATryn Phase 3 clinical program for treatment of preeclampsia in pregnant women

Heron initiates SUSTOL Phase 3 clinical trial for CINV prevention associated with emetogenic chemotherapy

CytRx’s aldoxorubicin receives European orphan medicinal product designation for treatment of advanced soft tissue sarcomas

Bariatric surgery patients report better quality of life

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Concert Pharmaceuticals announces 2013 year-end results; posts record revenue of $25.4M

Enrollment commences for Daiichi Sankyo's ENSURE-AF multinational phase 3 study in NVAF patients

ICON agrees to acquire Aptiv Solutions for $143.5 million

Amgen reports positive findings from AMG 145 Phase 3 studies in patients at risk for cardiovascular disease

New FDA Roadmap App helps sponsors improve clinical research

Cheap drug holds promise of treating heart attack patients

Mechanical circulatory assist device may have untapped potential in heart surgery patients, say physicians

Poor blood pressure control increases stroke risk in patients with atrial fibrillation

Device to improve blood flow implanted in muscular dystrophy patient

Experts in brain and spinal cord injuries to discuss treatment approaches at 23rd Annual Meeting of AMSSM

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer